BRIEF-Achillion announces data from phase 2 trial for combination treatment for Genotype 1 Treatment-Naïve HCV
September 23, 2016 at 12:04 PM EDT
* Announces 100 pct SVR12 In The 6-Week and 8-week cohorts in Janssen'S phase 2 trial evaluating the triple combination treatment regimen including odalasvir, al-335, and simeprevir for genotype 1 treatment-naïve hcv
